SIGA TechnologiesSIGA
About: SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
Employees: 45
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
44% more call options, than puts
Call options by funds: $4.02M | Put options by funds: $2.79M
22% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 51
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
0% more funds holding
Funds holding: 169 [Q3] → 169 (+0) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]
1.58% less ownership
Funds ownership: 49.95% [Q3] → 48.37% (-1.58%) [Q4]
14% less capital invested
Capital invested by funds: $241M [Q3] → $208M (-$33.1M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for SIGA.
Financial journalist opinion
Based on 6 articles about SIGA published over the past 30 days









